Papp KA, et al. – A comparative assessment was conducted of the outcomes between adalimumab and etanercept in the treatment of moderate to severe plaque psoriasis. A correlation was brought to light between adalimumab treatment for moderate to severe plaque psoriasis with greater PASI reduction, higher rates of resolution of skin signs and symptoms, and greater improvements in dermatological life quality, compared with etanercept.